Inhibition of Fatty Acid β-Oxidation by Fatty Acid Binding Protein 4 Induces Ferroptosis in HK2 Cells Under High Glucose Conditions
Endocrinology and Metabolism · 30.04.2023 · 38 (2) · 226-244
DOI: 10.3803/enm.2022.1604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology and Metabolism, erschienen am 30.04.2023. Verfasst von Jiasi Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Kidney and Urology Center, The Seventh Affiliated Hospital, Sun Yat-sen University, China. Hauptthemen laut MEDLINE: Ferroptosis. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanming Project of Medicine in Shenzhen, National Nature Science Foundation of China, The Shenzhen Science and Technology Innovation Committee of Guangdong Province of China.
Abstract (Originalsprache)
Background
Ferroptosis, which is caused by an iron-dependent accumulation of lipid hydroperoxides, is a type of cell death linked to diabetic kidney disease (DKD). Previous research has shown that fatty acid binding protein 4 (FABP4) is involved in the regulation of ferroptosis in diabetic retinopathy. The present study was constructed to explore the role of FABP4 in the regulation of ferroptosis in DKD.
Methods
We first detected the expression of FABP4 and proteins related to ferroptosis in renal biopsies of patients with DKD. Then, we used a FABP4 inhibitor and small interfering RNA to investigate the role of FABP4 in ferroptosis induced by high glucose in human renal proximal tubular epithelial (HG-HK2) cells.
Results
In kidney biopsies of DKD patients, the expression of FABP4 was elevated, whereas carnitine palmitoyltransferase-1A (CP-T1A), glutathione peroxidase 4, ferritin heavy chain, and ferritin light chain showed reduced expression. In HG-HK2 cells, the induction of ferroptosis was accompanied by an increase in FABP4. Inhibition of FABP4 in HG-HK2 cells changed the redox state, sup-pressing the production of reactive oxygen species, ferrous iron (Fe2+), and malondialdehyde, increasing superoxide dismutase, and reversing ferroptosis-associated mitochondrial damage. The inhibition of FABP4 also increased the expression of CPT1A, reversed lipid deposition, and restored impaired fatty acid β-oxidation. In addition, the inhibition of CPT1A could induce ferroptosis in HK2 cells.
Conclusion
Our results suggest that FABP4 mediates ferroptosis in HG-HK2 cells by inhibiting fatty acid β-oxidation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Kidney and Urology Center, The Seventh Affiliated Hospital, Sun Yat-sen University, China.
- Renal Division, Peking University Shenzhen Hospital, Shenzhen, China.
Förderung
- Sanming Project of Medicine in Shenzhen
- National Nature Science Foundation of China
- The Shenzhen Science and Technology Innovation Committee of Guangdong Province of China
Zitieren
APA
Chen, J., Wu, K., Lei, Y., Huang, M., Cheng, L., Guan, H., Lin, J., Zhong, M., Wang, X., & Zheng, Z. (2023). Inhibition of Fatty Acid β-Oxidation by Fatty Acid Binding Protein 4 Induces Ferroptosis in HK2 Cells Under High Glucose Conditions. Endocrinology and Metabolism, 38(2), 226-244. https://doi.org/10.3803/enm.2022.1604
Vancouver
Chen J, Wu K, Lei Y, Huang M, Cheng L, Guan H, et al. Inhibition of Fatty Acid β-Oxidation by Fatty Acid Binding Protein 4 Induces Ferroptosis in HK2 Cells Under High Glucose Conditions. Endocrinology and Metabolism. 2023;38(2):226-244. doi:10.3803/enm.2022.1604
BibTeX
@article{Chen2023,
author = {Chen, Jiasi and Wu, Keping and Lei, Yan and Huang, Mingcheng and Cheng, Lokyu and Guan, Hui and Lin, Jiawen and Zhong, Ming and Wang, Xiaohua and Zheng, Zhihua},
title = {Inhibition of Fatty Acid β-Oxidation by Fatty Acid Binding Protein 4 Induces Ferroptosis in HK2 Cells Under High Glucose Conditions},
journal = {Endocrinology and Metabolism},
year = {2023},
volume = {38},
number = {2},
pages = {226--244},
doi = {10.3803/enm.2022.1604}
}
EUVIMED